

Applicants concur that the cited language, e.g., page 3, paragraph 2, does not refer to amendments made after the time of filing of the present reissue examination. However, the language of page 3, paragraph 3 (e.g., the paragraph following the header "Statement as to additional errors under 37 C.F.R. §1.75(b)(1)" of the Supplemental Reissue Declaration filed on May 26, 2005 is fully compliant with the requirements of 37 C.F.R. §1.75 and MPEP 1414.01. More particularly, page 3, paragraph 3 of the May 26, 2005 declaration states:

In accordance with 35 C.F.R. §1.75(b)(1), applicant states that all errors being corrected in this reissue application which are not covered by the original reissue declaration in said application arose without deceptive intention on the part of the applicant.


Accordingly, Applicants respectfully request reconsideration and withdrawal of this rejection.

In view of the above, it is respectfully submitted that all of the claims are in condition for allowance. The issuance of a Notice of Allowance is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Novartis Institutes for BioMedical Research, Inc.
400 Technology Square
Cambridge, MA 02139

(617) 871-3105
Date: February 5, 2008

Respectfully submitted,



John B. Alexander
Attorney for Applicants
Reg. No. 48,399